TWiV reviews the FDA decision to update COVID-19 vaccine boosters in the fall, the meaning of fatigue with respect to long COVID, and a skin volatile induced by flavivirus reproduction that attracts mosquitoes to the infected host.

In COVID-19 clinical update #123, Dr. Griffin discusses rapid diagnostic testing in response to the monkeypox outbreak, leading causes of death in the US during the COVID-19 pandemic, antibody evasion by subvariants, broadly-neutralizing antibodies against emerging variants, factors associated with severe outcomes among hospitalized immunocompromised adults, measurement of the burden of hospitalizations during the pandemic, parental vaccine hesitancy in diverse communities, evaluating saliva sampling to improve access to diagnosis in low-resource settings, oral sabizabulin for high-risk hospitalized adults, lower-risk of multisystem inflammatory syndrome in children, and neurovascular injury with complement activation and inflammation during infection.

In COVID-19 clinical update #122, Dr. Griffin discusses vaccine availability and coverage among children, post-infection health impairments in children and adolescents, infection detection using salvia and nasopharyngeal samples, effectiveness of vaccines during delta dominance, durability…

TWiV discusses the recent decision by an FDA advisory committee to update COVID vaccines for the fall, the monkeypox virus outbreak, and the finding that enteric viruses infect the salivary glands and are transmitted through saliva.

In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

TWiV explains the meaning of vaccine-derived poliovirus found in London sewage, risk of long COVID after infections with Delta or Omicron variants of SARS-CoV-2, and enhancers of innate immune signaling as broad-spectrum antivirals. Hosts: Vincent Racaniello,…

In COVID-19 clinical update #120, Dr. Griffin discusses outcomes of SARS-CoV-2 reinfection, CDC recommendation for vaccines in young children, neurodevelopment outcomes in infants of mothers testing positive for COVID during pregnancy, efficacy of monoclonal antibodies and antivirals in hamsters, rebound phenomenon after PAXLOVID in high-risk persons, hospitalization for infection after PAXLOVID treatment, and risk of long COVID with different variants.

In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.